文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

基于患者的 iPSC 衍生肝细胞模型揭示了酒精相关性肝硬化发病机制的生物能量学见解。

A patient-based iPSC-derived hepatocyte model of alcohol-associated cirrhosis reveals bioenergetic insights into disease pathogenesis.

机构信息

Laboratory of Neurogenetics, National Institute on Alcohol Abuse and Alcoholism, NIH, Bethesda, MD, 20892, USA.

Division of Gastroenterology, Hepatology, and Nutrition, Department of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA, 23298, USA.

出版信息

Nat Commun. 2024 May 1;15(1):2869. doi: 10.1038/s41467-024-47085-y.


DOI:10.1038/s41467-024-47085-y
PMID:38693144
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11063145/
Abstract

Only ~20% of heavy drinkers develop alcohol cirrhosis (AC). While differences in metabolism, inflammation, signaling, microbiome signatures and genetic variations have been tied to the pathogenesis of AC, the key underlying mechanisms for this interindividual variability, remain to be fully elucidated. Induced pluripotent stem cell-derived hepatocytes (iHLCs) from patients with AC and healthy controls differ transcriptomically, bioenergetically and histologically. They include a greater number of lipid droplets (LDs) and LD-associated mitochondria compared to control cells. These pre-pathologic indicators are effectively reversed by Aramchol, an inhibitor of stearoyl-CoA desaturase. Bioenergetically, AC iHLCs have lower spare capacity, slower ATP production and their mitochondrial fuel flexibility towards fatty acids and glutamate is weakened. MARC1 and PNPLA3, genes implicated by GWAS in alcohol cirrhosis, show to correlate with lipid droplet-associated and mitochondria-mediated oxidative damage in AC iHLCs. Knockdown of PNPLA3 expression exacerbates mitochondrial deficits and leads to lipid droplets alterations. These findings suggest that differences in mitochondrial bioenergetics and lipid droplet formation are intrinsic to AC hepatocytes and can play a role in its pathogenesis.

摘要

仅有约 20%的重度饮酒者会发展为酒精性肝硬化(AC)。虽然代谢、炎症、信号转导、微生物组特征和遗传变异的差异与 AC 的发病机制有关,但导致这种个体间差异的关键潜在机制仍有待充分阐明。来自 AC 患者和健康对照者的诱导多能干细胞衍生的肝细胞(iHLCs)在转录组、生物能量和组织学上存在差异。与对照细胞相比,它们包含更多的脂滴(LDs)和与 LD 相关的线粒体。与对照细胞相比,这些前病理指标可被硬脂酰辅酶 A 去饱和酶抑制剂 Aramchol 有效逆转。在生物能量学方面,AC iHLCs 的备用能力较低,ATP 生成速度较慢,其线粒体对脂肪酸和谷氨酸的燃料灵活性减弱。MARC1 和 PNPLA3 是通过全基因组关联研究(GWAS)发现与酒精性肝硬化相关的基因,它们与 AC iHLCs 中与脂滴相关和与线粒体介导的氧化损伤相关。PNPLA3 表达的敲低会加剧线粒体缺陷,并导致脂滴改变。这些发现表明,线粒体生物能量学和脂滴形成的差异是 AC 肝细胞的固有特征,并可能在其发病机制中发挥作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc2f/11063145/e3256f142aaa/41467_2024_47085_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc2f/11063145/8c350b7315b2/41467_2024_47085_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc2f/11063145/9a1bc795dd8b/41467_2024_47085_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc2f/11063145/84e8e57302f4/41467_2024_47085_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc2f/11063145/4c5c3aeaa927/41467_2024_47085_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc2f/11063145/820ad26a928e/41467_2024_47085_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc2f/11063145/f0f4ab2d6b35/41467_2024_47085_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc2f/11063145/1b52a608dfc6/41467_2024_47085_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc2f/11063145/e3256f142aaa/41467_2024_47085_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc2f/11063145/8c350b7315b2/41467_2024_47085_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc2f/11063145/9a1bc795dd8b/41467_2024_47085_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc2f/11063145/84e8e57302f4/41467_2024_47085_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc2f/11063145/4c5c3aeaa927/41467_2024_47085_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc2f/11063145/820ad26a928e/41467_2024_47085_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc2f/11063145/f0f4ab2d6b35/41467_2024_47085_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc2f/11063145/1b52a608dfc6/41467_2024_47085_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fc2f/11063145/e3256f142aaa/41467_2024_47085_Fig8_HTML.jpg

相似文献

[1]
A patient-based iPSC-derived hepatocyte model of alcohol-associated cirrhosis reveals bioenergetic insights into disease pathogenesis.

Nat Commun. 2024-5-1

[2]
A PNPLA3-Deficient iPSC-Derived Hepatocyte Screen Identifies Pathways to Potentially Reduce Steatosis in Metabolic Dysfunction-Associated Fatty Liver Disease.

Int J Mol Sci. 2024-7-2

[3]
Unlocking the influence of PNPLA3 mutations on lipolysis: Insights into lipid droplet formation and metabolic dynamics in metabolic dysfunction-associated steatotic liver disease.

Biochim Biophys Acta Gen Subj. 2025-3

[4]
Lipid droplet targeting of the lipase coactivator ABHD5 and the fatty liver disease-causing variant PNPLA3 I148M is required to promote liver steatosis.

J Biol Chem. 2025-2

[5]
The fatty liver disease-causing protein PNPLA3-I148M alters lipid droplet-Golgi dynamics.

Proc Natl Acad Sci U S A. 2024-4-30

[6]
PNPLA3 variant M148 causes resistance to starvation-mediated lipid droplet autophagy in human hepatocytes.

J Cell Biochem. 2018-9-1

[7]
PNPLA3(148M) is a gain-of-function mutation that promotes hepatic steatosis by inhibiting ATGL-mediated triglyceride hydrolysis.

J Hepatol. 2025-5

[8]
The Propensity of the Human Liver to Form Large Lipid Droplets Is Associated with PNPLA3 Polymorphism, Reduced INSIG1 and NPC1L1 Expression and Increased Fibrogenetic Capacity.

Int J Mol Sci. 2021-6-5

[9]
Human hepatocyte PNPLA3-148M exacerbates rapid non-alcoholic fatty liver disease development in chimeric mice.

Cell Rep. 2022-9-13

[10]
A unifying mathematical model of lipid droplet metabolism reveals key molecular players in the development of hepatic steatosis.

FEBS J. 2017-9-6

引用本文的文献

[1]
Nutrient environment improves drug metabolic activity in human iPSC-derived hepatocytes and HepG2.

Arch Toxicol. 2025-8-12

[2]
Comparative analysis of small molecule and growth factor-derived human induced pluripotent stem cell-derived hepatocyte-like cells.

Front Cell Dev Biol. 2025-6-26

[3]
Experimental Models to Investigate PNPLA3 in Liver Steatosis.

Liver Int. 2025-5

[4]
Downregulation of the MARC1 p.A165 risk allele reduces hepatocyte lipid content by increasing beta-oxidation.

Clin Mol Hepatol. 2025-4

[5]
Mesenchymal stem cells: A promising therapeutic avenue for non-alcoholic fatty liver disease.

World J Stem Cells. 2024-8-26

本文引用的文献

[1]
Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial.

Nat Med. 2021-10

[2]
Perspectives on Mitochondria-ER and Mitochondria-Lipid Droplet Contact in Hepatocytes and Hepatic Lipid Metabolism.

Cells. 2021-9-1

[3]
Oxidative Stress-A Key Player in the Course of Alcohol-Related Liver Disease.

J Clin Med. 2021-7-6

[4]
Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis.

JHEP Rep. 2021-1-28

[5]
Discordant hepatic fatty acid oxidation and triglyceride hydrolysis leads to liver disease.

JCI Insight. 2021-1-25

[6]
IL-17A/F enable cholangiocytes to restrict T cell-driven experimental cholangitis by upregulating PD-L1 expression.

J Hepatol. 2021-4

[7]
Mitochondrial Glutathione: Recent Insights and Role in Disease.

Antioxidants (Basel). 2020-9-24

[8]
Genome-wide Association Study and Meta-analysis on Alcohol-Associated Liver Cirrhosis Identifies Genetic Risk Factors.

Hepatology. 2021-5

[9]
Oxidative stress in alcohol-related liver disease.

World J Hepatol. 2020-7-27

[10]
Current status of hepatocyte-like cell therapy from stem cells.

Surg Today. 2021-3

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索